$KYMR
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Healthcare
Sector
Biotechnology
Industry
Nello Mainolfi
CEO
208
Employees
$77.91
Current Price
$6.50B
Market Cap
Insider Activity Statistics
Aggregated buying and selling activity by time period
| Period | Type | Insiders | Transactions | Value | Shares | Buy/Sell Ratio |
|---|---|---|---|---|---|---|
| 1 week | Buys | 0 | 0 | - | - | All Sells |
| Sells | 1 | 3 | $197,877.15 | 2,500 | ||
| 2 weeks | Buys | 0 | 0 | - | - | All Sells |
| Sells | 2 | 6 | $2,343,550.50 | 28,258 | ||
| 1 month | Buys | 0 | 0 | - | - | All Sells |
| Sells | 6 | 34 | $14,953,439.03 | 169,061 | ||
| 2 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 6 | 36 | $15,171,709.04 | 171,561 | ||
| 3 months | Buys | 0 | 0 | - | - | All Sells |
| Sells | 6 | 41 | $17,887,169.51 | 207,061 | ||
See activity going back 12 months โ create a free account | ||||||
Insider Transactions
Recent purchases and sales by company insiders
| Date | Insider | Type | Shares | Price | Value | Actions |
|---|---|---|---|---|---|---|
| Dec 31, 2025 | Mainolfi Nello Director | Sale | 6,014 | $78.52 | $472,211.46 | View Details |
54 more transactions available โ create a free account to see 12 months of history | ||||||
Showing 41โ41 of 41 transactions
Upcoming Earnings
Scheduled earnings reports
EPS
EstimatedN/A
ActualN/A
Revenue
EstimatedN/A
ActualN/A
Past Earnings
Historical earnings results
EPS
Estimated-$0.78
ActualN/A
Revenue
EstimatedN/A
ActualN/A
3 more earnings records available โ create a free account to see 12 months of history
Related Activity
Cross-company insider connections and cluster buy signals
Insiders Also Active At
Insiders at this company also hold positions or have traded at these companies:
$MDGL โ MADRIGAL PHARMACEUTICALS, INC.via BAKER BROS. ADVISORS LP$KOD โ Kodiak Sciences Inc.via BAKER BROS. ADVISORS LP$CELC โ Celcuity Inc.via BAKER BROS. ADVISORS LP$IMCR โ Immunocore Holdings plcvia BAKER BROS. ADVISORS LP$TRDA โ Entrada Therapeutics, Inc.via BAKER BROS. ADVISORS LP$DNLI โ Denali Therapeutics Inc.via BAKER BROS. ADVISORS LP